课题基金 / 基金详情

Randomized, double-blind, placebo-controlled, multi-center, proof of concept study to evaluate the effect of sildenafil citrate (Revatio) 20 mg TID on hemodynamics in patients with Portal- Pulmonary Arterial Hypertension (PPAH) Short title: Revatio Portal

Randomized, double-blind, placebo-controlled, multi-center, proof of concept study to evaluate the effect of sildenafil citrate (Revatio) 20 mg TID on hemodynamics in patients with Portal- Pulmonary Arterial Hypertension (PPAH) Short title: Revatio Portal
随机、双盲、安慰剂对照、多中心、概念验证研究，旨在评估枸橼酸西地那非 (Revatio) 20 mg TID 对门静脉肺动脉高压 (PPAH) 患者血流动力学的影响 简短标题：Revatio Portal
批准号：
255364
负责人：
Granton John T
金额：
$13.72万
依托单位：
University Health Network (Toronto)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2012
资助国家：
加拿大
项目状态：
已结题
起止时间：
2012-03-01 至 2015-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=255364&lang=en
关键词：
Portal Hypertension Pulmonary Hypertension Randomized Controlled Trial Sildenafil

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Patients with liver disease can develop a condition known as pulmonary hypertension. In pulmonary hypertension there is a progressive narrowing of the small blood vessels as they travel through the lung. This narrowing puts stress on the right side of the
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金